Publicacións en colaboración con investigadores/as de Hospital Xeral Calde (290)

2020

  1. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies

    Annals of the Rheumatic Diseases

2017

  1. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study

    HIV Medicine, Vol. 18, Núm. 7, pp. 482-489

2015

  1. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility

    American Journal of Human Genetics, Vol. 96, Núm. 4, pp. 565-580

  2. Erratum to "Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project" [Semin Arthritis Rheum 44 (2015) 618-626]

    Seminars in Arthritis and Rheumatism

2014

  1. Analysis of two autoimmunity genes, IRAK1 and MECP2, in giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 32, Núm. SUPPL.82

  2. Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients

    Annals of the Rheumatic Diseases

  3. Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 2, pp. 231-236

  4. Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 2, pp. 218-224

  5. Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis

    Journal of Rheumatology, Vol. 41, Núm. 3, pp. 429-436

  6. Sex differences in patients with systemic lupus erythematosus from Northwest Spain

    Rheumatology International, Vol. 34, Núm. 1, pp. 11-24

2013

  1. A case-control study suggests that the CCR6 locus is not involved in the susceptibility to giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 31, Núm. SUPPL.75

  2. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 3, pp. 365-371

  3. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients

    Annals of the Rheumatic Diseases

  4. Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 4, pp. 532-537

  5. Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 5, pp. 749-755

  6. CARD8 rs2043211 (p.C10X) polymorphism is not associated with disease susceptibility or cardiovascular events in spanish rheumatoid arthritis patients

    DNA and Cell Biology, Vol. 32, Núm. 1, pp. 28-33

  7. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 6, pp. 913-918

  8. Evidence of association of the NLRP1 gene with giant cell arteritis

    Annals of the Rheumatic Diseases

  9. Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 11, pp. 1882-1886

  10. Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 4, pp. 538-545